Corona vaccine unlikely before US Presidential elections says Moderna

Corona cases is increasing rapidly in the world. Meanwhile, the death toll from Corona continues to grow steadily. Scientists are busy preparing the Corona vaccine in many countries. Meanwhile, Trump has received a major setback in the preparations for the presidential election in the US. US President Trump has previously said that the Corona vaccine can be prepared before the presidential election, ie November 3. There has been a lot of politics and criticism about Trump’s statement. Meanwhile, Moderna, the company that is preparing this vaccine in the US, has said itself that Corona vaccine will not be available in the US before the presidential election.

A media report on Wednesday quoted the Chief Executive Officer (CEO) of the Moderna company as saying that a possible Corona vaccine from Moderna would not be ready to apply before the presidential election in November. Stéphane Bancel told a prestigious media company that he could not allow all sections of the US to distribute the vaccine before the next spring. News agency Reuters has questioned Moderna about this comment, to which no response has been received yet.

American company Moderna’s vaccine is ahead in the race to develop a safe and effective vaccine to combat the corona epidemic. Currently, the trial of this vaccine is in the third phase. Corona vaccine preparation has become a major issue in the US presidential election. It also became an important issue in the presidential debate on Tuesday between US President Donald Trump and Democratic Party presidential contender Joe Biden.

Encouraging first phase results

Scientists from around the world are working day and night in laboratories to develop the corona vaccine. In the same sequence, a trial by American biotech company Mordana was found to develop a strong immune response in the elderly against corona, and its side effects were not seen.

The vaccine, developed jointly by researchers from the US National Institute of Allergy and Infectious Diseases (NIAID) and the American biotech company Moderna, may be one of the potential vaccines for corona. The researchers said that although these are the results of the first test, they have exceeded expectations. The study, published in the New England Journal of Medicine, stated that the experimental vaccine mRNA-1273 did not have any negative effects on people older than 55 years.